Actual 5-year survival of patients with stage IIIB breast carcinoma: Phase II trial of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acid

Stefan Madajewicz, Daniela Matei, Patricia Hentschel, Andrzej Kudelka, William Abel, John J. Fiore, Noshir A. DaCosta, Lakshmi Pendyala

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Patients with stage IIIB breast carcinoma represent only a small proportion of women with breast cancer in western countries but may constitute up to 50% of cases in underdeveloped countries. The prognosis remains poor despite aggressive treatment. Nineteen patients (11 with inflammatory breast carcinoma) received at least three courses of neoadjuvant chemotherapy of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acid (MVAC/FA) followed by mastectomy. Six months of cyclophosphamide, methotrexate, and 5-fluorouracil were given after surgery. Radiation therapy followed chemotherapy. Seventy percent of patients achieved complete and 14% partial response after MVAC/FA chemotherapy alone. Eleven patients (58%) survived 5 years, and 30% survived at least 8 years. The addition of cisplatin in combination chemotherapy used as first-line treatment for stage IIIB breast carcinoma was well tolerated, resulted in higher response rates, and appeared to have an effect on overall survival.

Original languageEnglish (US)
Pages (from-to)463-467
Number of pages5
JournalCancer Investigation
Volume17
Issue number7
StatePublished - 1999
Externally publishedYes

Fingerprint

Leucovorin
Vinblastine
Methotrexate
Doxorubicin
Cisplatin
Breast Neoplasms
Survival
Drug Therapy
Inflammatory Breast Neoplasms
Mastectomy
Combination Drug Therapy
Fluorouracil
Cyclophosphamide
Radiotherapy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Actual 5-year survival of patients with stage IIIB breast carcinoma : Phase II trial of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acid. / Madajewicz, Stefan; Matei, Daniela; Hentschel, Patricia; Kudelka, Andrzej; Abel, William; Fiore, John J.; DaCosta, Noshir A.; Pendyala, Lakshmi.

In: Cancer Investigation, Vol. 17, No. 7, 1999, p. 463-467.

Research output: Contribution to journalArticle

Madajewicz, S, Matei, D, Hentschel, P, Kudelka, A, Abel, W, Fiore, JJ, DaCosta, NA & Pendyala, L 1999, 'Actual 5-year survival of patients with stage IIIB breast carcinoma: Phase II trial of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acid', Cancer Investigation, vol. 17, no. 7, pp. 463-467.
Madajewicz, Stefan ; Matei, Daniela ; Hentschel, Patricia ; Kudelka, Andrzej ; Abel, William ; Fiore, John J. ; DaCosta, Noshir A. ; Pendyala, Lakshmi. / Actual 5-year survival of patients with stage IIIB breast carcinoma : Phase II trial of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acid. In: Cancer Investigation. 1999 ; Vol. 17, No. 7. pp. 463-467.
@article{2367d78a14dd402ea74455f2a4f02d2f,
title = "Actual 5-year survival of patients with stage IIIB breast carcinoma: Phase II trial of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acid",
abstract = "Patients with stage IIIB breast carcinoma represent only a small proportion of women with breast cancer in western countries but may constitute up to 50{\%} of cases in underdeveloped countries. The prognosis remains poor despite aggressive treatment. Nineteen patients (11 with inflammatory breast carcinoma) received at least three courses of neoadjuvant chemotherapy of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acid (MVAC/FA) followed by mastectomy. Six months of cyclophosphamide, methotrexate, and 5-fluorouracil were given after surgery. Radiation therapy followed chemotherapy. Seventy percent of patients achieved complete and 14{\%} partial response after MVAC/FA chemotherapy alone. Eleven patients (58{\%}) survived 5 years, and 30{\%} survived at least 8 years. The addition of cisplatin in combination chemotherapy used as first-line treatment for stage IIIB breast carcinoma was well tolerated, resulted in higher response rates, and appeared to have an effect on overall survival.",
author = "Stefan Madajewicz and Daniela Matei and Patricia Hentschel and Andrzej Kudelka and William Abel and Fiore, {John J.} and DaCosta, {Noshir A.} and Lakshmi Pendyala",
year = "1999",
language = "English (US)",
volume = "17",
pages = "463--467",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Actual 5-year survival of patients with stage IIIB breast carcinoma

T2 - Phase II trial of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acid

AU - Madajewicz, Stefan

AU - Matei, Daniela

AU - Hentschel, Patricia

AU - Kudelka, Andrzej

AU - Abel, William

AU - Fiore, John J.

AU - DaCosta, Noshir A.

AU - Pendyala, Lakshmi

PY - 1999

Y1 - 1999

N2 - Patients with stage IIIB breast carcinoma represent only a small proportion of women with breast cancer in western countries but may constitute up to 50% of cases in underdeveloped countries. The prognosis remains poor despite aggressive treatment. Nineteen patients (11 with inflammatory breast carcinoma) received at least three courses of neoadjuvant chemotherapy of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acid (MVAC/FA) followed by mastectomy. Six months of cyclophosphamide, methotrexate, and 5-fluorouracil were given after surgery. Radiation therapy followed chemotherapy. Seventy percent of patients achieved complete and 14% partial response after MVAC/FA chemotherapy alone. Eleven patients (58%) survived 5 years, and 30% survived at least 8 years. The addition of cisplatin in combination chemotherapy used as first-line treatment for stage IIIB breast carcinoma was well tolerated, resulted in higher response rates, and appeared to have an effect on overall survival.

AB - Patients with stage IIIB breast carcinoma represent only a small proportion of women with breast cancer in western countries but may constitute up to 50% of cases in underdeveloped countries. The prognosis remains poor despite aggressive treatment. Nineteen patients (11 with inflammatory breast carcinoma) received at least three courses of neoadjuvant chemotherapy of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acid (MVAC/FA) followed by mastectomy. Six months of cyclophosphamide, methotrexate, and 5-fluorouracil were given after surgery. Radiation therapy followed chemotherapy. Seventy percent of patients achieved complete and 14% partial response after MVAC/FA chemotherapy alone. Eleven patients (58%) survived 5 years, and 30% survived at least 8 years. The addition of cisplatin in combination chemotherapy used as first-line treatment for stage IIIB breast carcinoma was well tolerated, resulted in higher response rates, and appeared to have an effect on overall survival.

UR - http://www.scopus.com/inward/record.url?scp=0032837093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032837093&partnerID=8YFLogxK

M3 - Article

C2 - 10518189

AN - SCOPUS:0032837093

VL - 17

SP - 463

EP - 467

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 7

ER -